Tazeen Ahmad

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares jumped nearly 24% on Monday morning after a panel of experts voted last Friday in favor of the company's DMD gene therapy for accelerated approval in treating patients with Duchenne muscular dystrophy (DMD). What Happened: The panel vote was split...

PepGen Inc’s (NASDAQ: PEPG) lead asset, PGN-EDO51 for Duchenne muscular dystrophy (DMD), is in phase 1 clinical trials in healthy volunteers with data expected by the end of the year, according to BofA Securities. The PepGen Analyst: Tazeen Ahmad initiated coverage of PepGen with a Buy rating...

Following Ascendis Pharma’s (NASDAQ: ASND) reporting of positive topline Phase III data for its PaTHway trial of TransCon PTH (TCP) in adults with hypoparathyroidism, the likelihood of success of its TCP has increased from 60% to 75%, according to BofA Securities. The Ascendis Pharma Analyst...

Most investors are likely familiar with the adage, "actions speak louder than words." That saying certainly applies to the executives and other corporate insiders buying and selling shares of their own company's stock. It's part of an executive's job to paint a rosy public...

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century Therapeutics Inc (NASDAQ: IPSC), an analyst at BofA Securities said in a note on...

The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels last year. Unfortunately for investors, many of the most popular 2021 IPO stocks have...

Pfizer, Inc. (NYSE: PFE)-BioNTech SE (NASDAQ: BNTX) suffered a setback last week after a FDA panel did not recommend a third dose of the duo's COVID-19 vaccine for the broader population. The Pfizer-BioNTech Analysts: Morgan Stanley analyst Matthew Harrison maintained an Equal-weight rating...

Praxis Precision Medicines Inc’s (NASDAQ: PRAX) lead asset has demonstrated encouraging data for central nervous system diseases and has a broad pipeline that targets both prevalent and rare disorders, according to BofA Securities. The Praxis Precision Medical Analyst: Tazeen Ahmad initiated...

Prelude Therapeutics Inc’s (NASDAQ: PRLD) share price represents “a particularly attractive buying opportunity,” and the stock has catalysts in the back half of the year, according to BofA Securities. The Prelude Therapeutics Analyst: Tazeen Ahmad upgraded Prelude Therapeutics...

A BofA Securities analyst is turning bullish on shares of Ultragenyx Pharmaceuticals (NASDAQ: RARE). Here's why.  The Ultragenyx Analyst: Tazeen Ahmad upgraded Ultragenyx from Neutral to Buy with a $162 price target.  The Ultragenyx Takeaways: Ultragenyx has three approved...

Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Sarepta Therapeutics Inc (NASDAQ: SRPT) render their stocks as top picks for the first half of 2021, according to an analyst at BofA...

Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local casino. Sports gamblers are still waiting for the return of Major League Baseball and other pro and college sports...

Despite optimistic expectations concerning label expansion for Clovis Oncology Inc's (NASDAQ: CLVS) Rubraca to include prostate cancer, an analyst at BofA Securities is turning bearish on the stock.  The Clovis Analyst Tazeen Ahmad downgraded Clovis shares from Neutral to Underperform...

Despite a coronavirus scare, the S&P 500 has held up relatively well do far in 2020 and is trading within a stone’s throw of all-time highs. With the market up so much in recent years, it can be difficult for small-time investors to find affordable stocks to buy at relatively low prices....

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), which derives a lion's share of its revenues from its cannabinoid seizure drug Epidiolex, provides value for investors due to the potential for the drug to have wide utility over both orphan and non-orphan indications, according to BofA Securities....